Reading XERS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track XERS free→Reading XERS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track XERS free→QuarterlyIQ Insights · XERS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On June 11, 2026, the Company issued a press release announcing entry into the Exchange Agreements. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Special Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K relating to, among other things, the Exchange Agreements and the transactions contemplated thereby constitute forward-looking statements under The Private Securities Litigatio…
Unregistered Sales of Equity Securities. On June 10, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders (the “Noteholders”) of its 8.00% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which the Noteholders have agreed to exchange (the “Exchange”) approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of…
Results of Operations and Financial Condition. On May 7, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three months ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Sectio…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Retirement of Director Jeffrey Sherman On April 20, 2026, Dr. Jeffrey Sherman, a member of the Board of Directors (the “Board”) of Xeris Biopharma Holdings, Inc. (the “Company”), provided notice to the Company of his decision to retire from the Board and not stand for reelection at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual…
Results of Operations and Financial Condition. On March 2, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and twelve months ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for pu…
Other Events. On February 26, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release announcing that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act against two pharmaceutical companies (each, an "ANDA Filer") in the United States District Court for the District of New Jersey regarding each ANDA Filer's submission of an Abbreviated New Drug Application ("ANDA") to the U.S. F…
in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Results of Operations and Financial Condition. On November 6, 2025, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and nine months ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for…
Results of Operations and Financial Condition. On August 7, 2025, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and six months ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes…
Results of Operations and Financial Condition. On May 8, 2025, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three months ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Sectio…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director Ricki Fairley On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025. Ms. Fairley’s resignation was not because of any disagreement with the Comp…
Results of Operations and Financial Condition. On March 6, 2025, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and twelve months ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for pu…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Retirement of Mr. Ken Johnson as Senior Vice President, Global Development and Medical Affairs On February 24, 2025, Mr. Ken Johnson, Pharm.D. notified Xeris Biopharma Holdings, Inc. (the “Company”) of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.